Clinical Trials on Gastroenteritis in Canada

Total 586 results

UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
Boehringer Ingelheim

Completed

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Colitis, Ulcerative

Canada, United States, Spain, United Kingdom, Belgium, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Austria
Sanofi

Terminated

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis (FUSCIA)

Ulcerative Colitis

United States, Austria, Canada, France, Germany, Italy, Poland
Warner Chilcott

Completed

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Ulcerative Colitis

Poland, United States, Croatia, Romania, Canada
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
PPM Services S.A.

Terminated

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC (SEGMENT)

Ulcerative Colitis

United States, Hungary, Slovakia, Italy, Ukraine, Bulgaria, Poland, Latvia, Canada, France
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy

Diarrhea | Radiation Enteritis

United States, Canada
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Celgene

Completed

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Switzerland, Canada
Genentech, Inc.

Completed

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Belgium, Spain, New Zealand, United States, Czech Republic, Germany, Australia, United Kingdom, Israel, Hungary, Canada
Abivax S.A.

Completed

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Belgium, Poland, Spain, France, Germany, Italy, Slovenia, Canada, Belarus, Hungary, Czechia, Austria, United Kingdom, Serbia, Slovakia, Ukraine, United States
AbbVie

Completed

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Warner Chilcott

Terminated

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis (CAMPIII)

Ulcerative Colitis

United States, Canada, Croatia, Russian Federation, Poland, Romania
Warner Chilcott

Completed

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Ulcerative Colitis

United States, Canada, Puerto Rico
Ception Therapeutics

Completed

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Eosinophilic Esophagitis

United States, Canada
Janssen-Cilag Ltd.

Recruiting

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD)

Fistulizing Crohns Disease | Perianal Crohns Disease

Netherlands, United States, Belgium, Korea, Republic of, Taiwan, Israel, Japan, Canada, Hungary, Germany, Greece, United Kingdom, Australia, Spain, Saudi Arabia, Poland, Turkey, Portugal, Czechia, Italy, Jordan, France
Sublimity Therapeutics Holdco Limited
Dr. Falk Pharma GmbH

Terminated

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, United Kingdom, Serbia, Canada, Russian Federation, Poland, Israel, Romania, Ireland, Spain, Hungary, Ukraine, Belarus, Italy, Bulgaria, France, Germany
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis (Falcon)

Ulcerative Colitis

United States, France, Australia, Italy, Poland, Germany, Austria, Canada, Switzerland
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

Crohn's Disease

United States, France, Netherlands, Spain, Germany, Poland, Belgium, South Africa, Sweden, Israel, Korea, Republic of, Australia, Austria, Canada, Czechia, Denmark, Hungary, Italy, Japan, New Zealand, Norway, Slovakia, United Kingdom
Bausch Health Americas, Inc.

Completed

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Ulcerative Colitis

United States, Canada
Takeda

Terminated

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment (CALYPSO)

Gastrointestinal Diseases | Intestinal Diseases | Crohn Disease | Inflammatory Bowel Disease

Spain
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
GlaxoSmithKline

Terminated

Open-Label Extension Study of GSK1605786A (SHIELD-3)

Crohn's Disease

United States, France, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New Zealand, Po... and more
Université de Sherbrooke
Canadian Institutes of Health Research (CIHR); Western University, Canada; Agence...

Completed

Patient-Centred Innovations for Persons With Multimorbidity - Quebec (PACEinMM-QC)

Depression | Heart Failure | Stroke | Hypertension | Cardiovascular Disease | Diabetes | Ulcer | Cancer | Arthritis | Rheumatoid Arthritis | Musculoskeletal Pain | Asthma | Gastroesophageal Reflux | Dementia | Anxiety | HIV | Crohn's Disease | Osteoporosis | Ulcerative Colitis | Chronic Obstructive Pulmonary Disease (COPD) | Hyperlipi... and other conditions

Canada
Ception Therapeutics
Cephalon

Completed

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Canada
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD2)

Enterocolitis Clostridium Difficile Recurrent

United States, Canada
Celldex Therapeutics

Recruiting

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (EvolvE)

Eosinophilic Esophagitis

United States, Spain, United Kingdom, Canada, Italy, Poland, Australia, Germany
GlaxoSmithKline

Terminated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

Crohn's Disease

United States, France, Netherlands, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New... and more
Gilead Sciences

Recruiting

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

Ulcerative Colitis

United States, Australia, United Kingdom, Korea, Republic of, Japan, Italy, France, Canada, Switzerland, Austria, Germany, Hungary, Poland
Ferring Pharmaceuticals

Completed

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Bulgaria, Canada, Mexico, Poland, Serbia
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis (Touchstone)

Ulcerative Colitis

Netherlands, United States, Israel, Australia, Korea, Republic of, New Zealand, Hungary, Poland, Slovakia, Ukraine, Canada, Bulgaria, Greece, Russian Federation, Belgium
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Bristol-Myers Squibb

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, Belgium, Germany, Japan, France, Poland, Russian Federation, Spain, Australia, Canada, Israel, United Kingdom
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Colitis, Ulcerative

United States, Israel, Canada, Italy, United Kingdom, Hungary, Japan, Australia, China, Greece, Belgium, Croatia, Korea, Republic of, Poland, Czechia
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Bristol-Myers Squibb

Completed

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

Australia, United States, Canada, France, Mexico, Austria, Italy, Netherlands, Belgium, Germany, Brazil, Hungary, South Africa, Poland
Alimentiv Inc.
Takeda Development Center Americas, Inc.

Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)

Colitis, Ulcerative

Canada, United Kingdom, Poland, Italy, United States, Belgium, France, Netherlands, Belarus, Ukraine
Grupo Espanol de Trabajo en Enfermedad de Crohn...

Terminated

Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis (ATICCA)

Ulcerative Colitis

Spain, Portugal, Austria, Italy, Germany
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)

Ulcerative Colitis

United States, Canada, Poland, Japan, Belgium, Israel, Portugal, Korea, Republic of, France, Australia, Italy, Netherlands, Germany, United Kingdom
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Ferring Pharmaceuticals

Completed

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Serbia, Bulgaria, Canada, Mexico, Poland
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Netherlands, Poland, Belgium, France, Hungary, Lithuania, Canada, Czechia, Denmark, Georgia, Japan, Moldova, Republic of, Romania, United Kingdom
Pfizer

Terminated

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Ulcerative Colitis

Spain, United States, Korea, Republic of, Serbia, Canada, Poland, Japan, France, New Zealand, South Africa, Germany, Slovakia, Hungary, Belgium, Czechia, Italy, Netherlands, Russian Federation, Ukraine, United Kingdom
AbbVie

Completed

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Canada, Czechia, Hungary, Israel, Japan, New Zealand, Poland, Slovakia, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors (LAUREL)

Colitis, Ulcerative

Israel, United States, Hungary, India, Canada, Poland, Ukraine, Germany, Mexico, Brazil, Czechia, Slovakia, Denmark, South Africa, Italy
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis (GEMINI I)

Ulcerative Colitis

United States, Canada, Puerto Rico
Protagonist Therapeutics, Inc.

Terminated

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czechia, Germany, Hungary, Korea, Republic of, Latvia, Netherlands, New Zealand, Poland, Russian Federation, Serbia, Ukraine

Clinical Trials on Gastroenteritis in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations